Recombinant Human TSH (rhTSH): Use in Papillary and Follicular Thyroid Cancer

2006 ◽  
pp. 201-210
Author(s):  
Furio Pacini ◽  
Martin J. Schlumberger
Keyword(s):  
Thyroid Cancer ◽  
Follicular Thyroid Cancer ◽  
Recombinant Human Tsh

scholarly journals Clinical use of recombinant human TSH in thyroid cancer patients

2000 ◽  
pp. 557-563 ◽  
Author(s):  
M Schlumberger ◽  
M Ricard ◽  
F Pacini
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Hormone ◽  
Cancer Patients ◽  
Recurrent Disease ◽  
Clinical Use ◽  
Follicular Thyroid Cancer ◽  
Safe Alternative ◽  
Thyroid Hormone Withdrawal ◽  
Recombinant Human Tsh

Recombinant human TSH (rhTSH) is an effective and safe alternative to thyroid hormone withdrawal during the post-surgical follow-up of papillary and follicular thyroid cancer. Its clinical efficiency for the detection of persistent and recurrent disease is similar to that of thyroid hormone withdrawal. The main purpose for its use is to avoid hypothyroidism.

Abstract #1075 Metastatic Follicular Thyroid Cancer with Hemorrhagic Metastases to the Pituitary Gland

2018 ◽  
Vol 24 ◽  
pp. 258
Author(s):  
Regina Belokovskaya ◽  
Pietra Greenberg ◽  
Shira Saul
Keyword(s):  
Thyroid Cancer ◽  
Pituitary Gland ◽  
Follicular Thyroid Cancer

Abstract #1070 An Unusual Case of Metastatic Follicular Thyroid Cancer 40 Years After Initial Diagnosis

2018 ◽  
Vol 24 ◽  
pp. 255
Author(s):  
Lakshmi Menon ◽  
Yuanjie Mao ◽  
Sanaz Abedzadeh-Anaraki ◽  
Spyridoula Maraka
Keyword(s):  
Thyroid Cancer ◽  
Unusual Case ◽  
Initial Diagnosis ◽  
Follicular Thyroid Cancer

New markers of follicular thyroid cancer found with wide-panel next-generation sequencing

2018 ◽  
Author(s):  
Martyna Borowczyk ◽  
Ewelina Szczepanek-Parulska ◽  
Szymon Debicki ◽  
Bartlomiej Budny ◽  
Malgorzata Janicka-Jedynska ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Next Generation Sequencing ◽  
Next Generation ◽  
Follicular Thyroid Cancer ◽  
Generation Sequencing

A challenging case of progressive follicular thyroid cancer

2018 ◽  
Author(s):  
Shazia Hussain ◽  
Carmel Brennan ◽  
Nick Plowman ◽  
Kate Newbold ◽  
William Drake
Keyword(s):  
Thyroid Cancer ◽  
Follicular Thyroid Cancer

Profiling circulating microRNAs as serum biomarkers for thyroid cancer recurrence before and after recombinant human TSH stimulation

2019 ◽  
Author(s):  
Jelena Jankovic-Miljus ◽  
Leon Wert-Lamas ◽  
Maria Augusta Guillen-Sacoto ◽  
Andrea Martinez-Cano ◽  
Pilar Santisteban ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Recurrence ◽  
Serum Biomarkers ◽  
Circulating Micrornas ◽  
Recombinant Human Tsh ◽  
Before And After ◽  
Thyroid Cancer Recurrence ◽  
Tsh Stimulation

Treating papillary and follicular thyroid cancer in children and young people: Single UK-center experience between 2003 and 2018

2020 ◽  
Author(s):  
Mechteld C de Jong ◽  
Mark N Gaze ◽  
Elwira Szychot ◽  
Virginia Rozalén García ◽  
Caroline Brain ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Young People ◽  
Follicular Thyroid Cancer ◽  
Children And Young People ◽  
Cancer In Children

Prognostic value of nuclear DNA content in papillary and follicular thyroid cancer

1988 ◽  
Vol 12 (4) ◽  
pp. 503-507 ◽  
Author(s):  
Jaap F. Hamming ◽  
Lodewijk J. D. M. Schelfhout ◽  
Cees J. Cornelisse ◽  
Cornelis J. H. van de Velde ◽  
Bernard M. Goslings ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Dna Content ◽  
Prognostic Value ◽  
Nuclear Dna ◽  
Nuclear Dna Content ◽  
Follicular Thyroid Cancer

scholarly journals Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer

Cancers ◽  
2021 ◽  
Vol 13 (14) ◽  
pp. 3487
Author(s):  
Yu-Ling Lu ◽  
Ming-Hsien Wu ◽  
Yi-Yin Lee ◽  
Ting-Chao Chou ◽  
Richard J. Wong ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cell Lines ◽  
Differentiated Thyroid Cancer ◽  
Xenograft Model ◽  
In Vivo Studies ◽  
Follicular Thyroid Cancer ◽  
Biomarker Analysis ◽  
Cancer Tumor

Differentiated thyroid cancer (DTC) patients are usually known for their excellent prognoses. However, some patients with DTC develop refractory disease and require novel therapies with different therapeutic mechanisms. Targeting Wee1 with adavosertib has emerged as a novel strategy for cancer therapy. We determined the effects of adavosertib in four DTC cell lines. Adavosertib induces cell growth inhibition in a dose-dependent fashion. Cell cycle analyses revealed that cells were accumulated in the G2/M phase and apoptosis was induced by adavosertib in the four DTC tumor cell lines. The sensitivity of adavosertib correlated with baseline Wee1 expression. In vivo studies showed that adavosertib significantly inhibited the xenograft growth of papillary and follicular thyroid cancer tumor models. Adavosertib therapy, combined with dabrafenib and trametinib, had strong synergism in vitro, and revealed robust tumor growth suppression in vivo in a xenograft model of papillary thyroid cancer harboring mutant BRAFV600E, without appreciable toxicity. Furthermore, combination of adavosertib with lenvatinib was more effective than either agent alone in a xenograft model of follicular thyroid cancer. These results show that adavosertib has the potential in treating DTC.

Sign in / Sign up

Export Citation Format

Share Document